Verrica Pharmaceuticals (VRCA) Income from Continuing Operations (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Income from Continuing Operations of 10545000.0 for Q1 2026, down 5.49% year-over-year from 11157808.83 in Q1 2025, and down 1.63% quarter-over-quarter from 10376000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 10545000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 5.49% year-over-year to 10545000.0; the TTM figure through Mar 2026 stood at 26185000.0 (up 63.14% YoY), while the FY2025 annual figure was 84994000.0, up 37.22% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10545000.0, down from 10376000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1496000.0 in Q3 2022, with the low at 2706930000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 10545000.0 (2026), against an average of 170513235.29.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 111.65% in 2022, then tumbled 24759.31% in 2024.
- Verrica Pharmaceuticals' Income from Continuing Operations stood at 6309000.0 in 2022, then sank by 283.21% to 24177000.0 in 2023, then soared by 46.49% to 12938000.0 in 2024, then grew by 19.8% to 10376000.0 in 2025, then decreased by 1.63% to 10545000.0 in 2026.
- Business Quant data shows VRCA's Income from Continuing Operations at 10545000.0 in Q1 2026, 10376000.0 in Q4 2025, and 4094000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -13.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.51 Mn |
| Mar 31, 2026 | -10.55 Mn |
| Dec 31, 2025 | -10.38 Mn |
| Sep 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -1.17 Mn |
| Mar 31, 2025 | -10.00 Mn |
| Dec 31, 2024 | -12.94 Mn |
| Sep 30, 2024 | -30.93 Mn |
| Jun 30, 2024 | -17.18 Mn |
| Mar 31, 2024 | -2.71 Bn |
| Dec 31, 2023 | -24.18 Mn |
| Sep 30, 2023 | -24.75 Mn |
| Jun 30, 2023 | -10.99 Mn |
| Mar 31, 2023 | -10.89 Mn |
| Dec 31, 2022 | -6.31 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Jun 30, 2022 | -10.48 Mn |
| Mar 31, 2022 | -8.47 Mn |
| Dec 31, 2021 | -10.63 Mn |
| Sep 30, 2021 | -12.84 Mn |